Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What is the anticipated market size of the colon targeting drug delivery industry over the next few years?
The colon targeting drug delivery market size has grown strongly in recent years. It will grow from $1.39 billion in 2024 to $1.51 billion in 2025 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to the rising prevalence of colorectal diseases, increasing focus on localized drug delivery, the need for improved patient compliance, and the emergence of biologics and peptides.
The colon targeting drug delivery market size is expected to see strong growth in the next few years. It will grow to $2.07 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to the development of stimuli-responsive and nanotechnology-based delivery systems, growth in contract research and manufacturing services, regulatory agencies offering incentives and faster approval pathways, and targeted delivery of biologics and biosimilars. Major trends in the forecast period include advancement in pH-responsive, personalized medicine integration, use of AI and digital tools in formulation design, and increasing focus on oral colon delivery.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24194&type=smp
What emerging drivers are expected to shape the future of the colon targeting drug delivery market?
The rising prevalence of gastrointestinal diseases is expected to propel the growth of the colon targeting drug delivery market going forward. Gastrointestinal diseases refer to disorders affecting the digestive tract, including the stomach, intestines, and associated organs. The prevalence of gastrointestinal diseases is growing due to unhealthy dietary habits, which include excessive consumption of processed foods and low fiber intake that disrupt gut health and digestion. Colon targeting drug delivery is used in gastrointestinal diseases to ensure precise drug release at the site of inflammation or infection, enhancing therapeutic effectiveness and reducing systemic side effects. For instance, in June 2023, according to Crohn’s and Colitis Canada, a nonprofit organization, the number of individuals affected by inflammatory bowel disease is projected to increase from 322,600 in 2023 (representing 0.8% of the population) to 470,000 by 2035 (1.1% of the population). Therefore, the rising prevalence of gastrointestinal diseases is driving the growth of the colon targeting drug delivery market.
What emerging segments are shaping the future landscape of the colon targeting drug delivery industry?
The colon targeting drug delivery market covered in this report is segmented –
1) By Dosage Form: Tablets, Capsules, Microspheres, Nanoparticles, Other Dosage Form
2) By Technology: pH-Sensitive Systems, Time-Dependent Systems, Microbially Triggered Systems, Pressure-Controlled Systems, Other Technologies
3) By Application: Inflammatory Bowel Disease, Colorectal Cancer, Infectious Diseases, Other Application
4) By End-User: Hospitals, Clinics, Research Institutes, Other End-Users
Subsegments:
1) By Tablets: Extended-Release Tablets, Enteric-Coated Tablets, Osmotic Pump Tablets
2) By Capsules: Hard Gelatin Capsules, Soft Gelatin Capsules, Enteric-Coated Capsules
3) By Microspheres: Polymeric Microspheres, Biodegradable Microspheres, Non-biodegradable Microspheres
4) By Nanoparticles: Polymeric Nanoparticles, Solid Lipid Nanoparticles, Dendrimers, Lipid-Polymer Hybrid Nanoparticles
4) By Other Dosage Form: Films, Injections, Hydrogels, Suppositories
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/colon-targeting-drug-delivery-global-market-report
What are the top market trends driving innovation in the colon targeting drug delivery industry?
Major companies operating in the colon targeting drug delivery market are focusing on developing innovative drug delivery solutions, such as functional oral dosage forms, to improve targeted drug release, enhance therapeutic efficacy, and minimize side effects. Functional oral dosage forms are used in colon targeting drug delivery to protect active pharmaceutical ingredients from degradation in the upper gastrointestinal tract and ensure their controlled release specifically in the colon. For instance, in September 2024, Evonik Industries AG, a Germany-based specialty chemicals company, launched EUDRACAP Functional, a ready-to-fill capsule technology for the targeted delivery of oral drugs to the colon. This advanced solution enables precise release by using pH-sensitive polymers that dissolve only at specific intestinal pH levels, ensuring the API reaches the colon intact. By enabling oral delivery of complex APIs such as peptides and probiotics, EUDRACAP Functional supports the development of patient-friendly therapies and expands the possibilities for treating chronic gastrointestinal disorders with greater accuracy and reduced systemic exposure.
How are key players in the colon targeting drug delivery market strengthening their market position?
Major companies operating in the colon targeting drug delivery market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Evonik Industries AG, Teva Pharmaceutical Industries Ltd., Baxter International Inc., Lonza Pharma AG, Ferring Pharmaceuticals Company Limited, Salix Pharmaceuticals Ltd., Tillotts Pharma AG, BDD Pharma Ltd., Tharimmune Inc.
Which geographic areas are contributing significantly to the growth of the colon targeting drug delivery sector?
North America was the largest region in the colon targeting drug delivery market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the colon targeting drug delivery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Colon Targeting Drug Delivery Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/customise?id=24194&type=smp
Need Customized Data On Colon Targeting Drug Delivery Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24194&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
